BC057022 Inhibitors
BC057022, a protein of emerging interest, is implicated in cellular processes associated with proliferation, survival, and transcriptional regulation. Despite ongoing investigations, its precise function remains to be fully elucidated. The intricate regulatory networks that converge on BC057022 make it a compelling target for research focused on understanding fundamental cellular processes. Atrasentan, an endothelin receptor antagonist, interferes with the endothelin signaling pathway, potentially influencing BC057022 indirectly. This interference may impact BC057022 expression and function, altering cellular processes associated with proliferation and survival. SB431542, a TGF-β receptor inhibitor, disrupts the TGF-β signaling pathway, which crosstalks with BC057022 signaling, offering another avenue for potential modulation of BC057022 expression and function.
Wortmannin, a PI3K inhibitor, and PD98059, a MEK inhibitor targeting the MAPK/ERK pathway, provide additional insights into potential regulatory mechanisms. These compounds disrupt critical signaling pathways that intersect with BC057022, suggesting a role in modulating its expression and function. Rapamycin and AZD8055, mTOR inhibitors, target the mTOR pathway, providing potential avenues for influencing BC057022 and its associated cellular processes. Furthermore, SB203580, a p38 MAPK inhibitor, Gefitinib, an EGFR inhibitor, and Trametinib, a MEK inhibitor targeting the MAPK/ERK pathway, expand the repertoire of potential BC057022 modulators. Their impacts on specific signaling pathways may lead to alterations in BC057022 expression and function. In conclusion, BC057022 inhibitors offer valuable tools for unraveling the intricacies of this protein's function and the regulatory networks that govern it. As research advances, a comprehensive understanding of BC057022 and its modulation by these inhibitors will undoubtedly contribute to our knowledge of fundamental cellular processes, paving the way for future discoveries in cell biology and signaling.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Atrasentan Hydrochloride | 195733-43-8 | sc-503157 | 50 mg | $490.00 | ||
Endothelin receptor antagonist. Atrasentan Hydrochloride interferes with the endothelin signaling pathway, potentially influencing BC057022 indirectly. This interference may impact BC057022 expression and function, altering cellular processes associated with proliferation and survival. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
TGF-β receptor inhibitor. SB431542 disrupts the TGF-β signaling pathway, which crosstalks with BC057022 signaling. This interference may influence BC057022 expression and function, impacting cellular processes associated with transcriptional regulation and cell growth. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3K inhibitor. Wortmannin disrupts the PI3K/Akt pathway, potentially influencing BC057022 indirectly. This interference may impact BC057022 expression and function, altering cellular processes associated with transcriptional regulation and cell growth. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
MEK inhibitor targeting the MAPK/ERK pathway. PD98059 disrupts the MAPK/ERK pathway, potentially affecting BC057022 expression and function in the context of cellular growth and differentiation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor. Rapamycin disrupts the mTOR pathway, which crosstalks with BC057022 signaling. This interference may influence BC057022 expression and function, impacting cellular processes associated with cell growth and proliferation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor targeting the PI3K/Akt pathway. LY294002 disrupts the PI3K/Akt pathway, which crosstalks with BC057022 signaling. This interference may influence BC057022 expression and function, impacting cellular processes associated with transcriptional regulation and cell growth. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
p38 MAPK inhibitor. PD 169316 influences the p38 MAPK pathway, potentially modulating BC057022 expression and function in specific cellular contexts. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR inhibitor. Gefitinib targets the EGFR pathway, potentially influencing BC057022 indirectly. This interference may impact BC057022 expression and function, altering cellular processes associated with transcriptional regulation and cell growth. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitor targeting the MAPK/ERK pathway. Trametinib disrupts the MAPK/ERK pathway, potentially affecting BC057022 expression and function in the context of cellular growth and differentiation. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
mTOR inhibitor. AZD8055 disrupts the mTOR pathway, which crosstalks with BC057022 signaling. This interference may influence BC057022 expression and function, impacting cellular processes associated with cell growth and proliferation. | ||||||